Relaxin Inhibits Cardiac Fibrosis in Diabetic Rats: Roles of Protein Kinase Cδ

Abstract

Relaxin (Rlx) is known to antagonize diabetic cardiac fibrosis. However, its mechanism is poorly understood. Protein kinase Cδ (PKCδ) plays a crucial role in diabetic cardiomyopathy (DCM). This study explored the involvement of PKCδ in Rlx’s capacity of suppressing cardiac fibrosis in a rat model of type 2 diabetes mellitus (DM). Type 2 DM of 8-week-old male Sprague–Dawley (SD) rats was induced by a high-fat diet and the injection of streptozocin (STZ, 40 mg/kg). Fourteen-week-old rats with DM and rats in control group which were pre-treated for 1 week with human recombinant relaxin (rhRlx, 30 μg/kg.d), were assessed to detect cardiac fibrosis and PKCδ expression with Western blot. Cardiac fibroblasts of neonatal rats were treated for 72 h with rhRlx (100 ng/ml) under high glucose (HG). Western blot was utilized for detecting the membranous and cytoplasmic protein expressions of PKCδ. The effects of rhRlx and PKCδ inhibitor (rottlerin) were assessed either alone or in combination on the HG-induced proliferation and differentiation of cardiac fibroblasts and the release of collagen I.

Rlx treatment inhibited the differentiation of cardiac fibroblasts and the expression of collagen I. The expression of PKCδ was regulated by Rlx in diabetic rats and cardiac fibroblasts under HG condition. The effects of Rlx upon the proliferation and differentiation of cardiac fibroblasts and the excretion of collagen I under HG were blunted by rottlerin. Rlx suppressed cardiac fibrosis in type 2 diabetic rats. This beneficial effect was associated with its ability of modulating the expression of PKCδ.

Key words

relaxin - diabetes - cardiac fibrosis - protein kinase Cδ

• References

• 1 Gu HP, Lin S, Xu M. et al. Up-regulating relaxin expression by g-quadruplex interactive ligand to achieve antifibrotic action. Endocrinology 2012; 153: 3692-3700
• 2 Samuel CS, Cendrawan S, Gao XM. et al. Relaxin remodels fibrotic healing following myocardial infarction. Lab Invest 2011; 91: 675-690
• 3 Bani D, Nistri S, Formigli L. et al. Prominent role of relaxin in improving postinfarction heart remodeling. Ann N Y Acad Sci 2009; 1160: 269-277
• 4 Lekgabe ED, Kiriazis H, Zhao C. et al. Relaxin reverses cardiac and renal fibrosis in spontaneously hypertensive rats. Hypertension 2005; 46: 412-418
• 5 Mookerjee I, Unemori EN, DU XJ. et al. Relaxin modulates fibroblast function, collagen production and matrix metalloproteinase-2 expression by cardiac fibroblasts. Ann N Y Acad Sci 2005; 1041: 190-193
• 6 Samuel CS, Unemori EN, Mookerjee I. et al. Relaxin modulates cardiac fibroblast proliferation, differentiation, and collagen production and reverses cardiac fibrosis in vivo. Endocrinology 2004; 145: 4125-4133
• 7 Du XJ, Samuel CS, Gao XM. et al. Increased myocardial collagen and ventricular diastolic dysfunction in relaxin deficient mice: A gender-specific phenotype. Cardiovasc Res 2003; 57: 395-404
• 8 Zhou X, Chen X, Cai JJ. et al. Relaxin inhibits cardiac fibrosis and endothelial-mesenchymal transition via the Notch pathway. Drug Des Devel Ther 2015; 11: 4599-4611
• 9 Samuel CS, Bodaragama H, Chew JY. et al. Serelaxin is a more efficacious antifibrotic than enalapril in an experimental model of heart disease. Hypertension 2014; 64: 315-322
• 10 Wang YP, Wang P, Dong L. et al. Relaxin inhibit cardiac fibrosis induced by phorbol 12-myristate 13-acetate. Biomed Environ Sci 2014; 27: 138-141
• 11 Samuel CS, Hewitson TD, Zhang Y. et al. Relaxin ameliorates fibrosis in experimental diabetic cardiomyopathy. Endocrinology 2008; 149: 3286-3293
• 12 Wang P, Li HW, Wang YP. et al. Effects of recombinant human relaxin upon proliferation of cardiac fibroblast and synthesis of collagen under high glucose condition. J Endocrinol Invest 2009; 32: 242-247
• 13 Zhang X, Ma X, Zhao M. et al. H2 and H3 relaxin inhibit high glucose-induced apoptosis in neonatal rat ventricular myocytes. Biochimie 2015; 108: 59-67
• 14 Bani D, Pini A, Yue SK. Relaxin, insulin and diabetes: An intriguing connection. Curr Diabetes Rev 2012; 8: 329-335
• 15 Shaw EE, Wood P, Kulpa J. et al. Relaxin alters cardiac myofilament function through a PKC-dependent pathway. Am J Physiol Heart Circ Physiol 2009; 297: H29-H36
• 16 Guo M, Wu MH, Korompai F. et al. Up-regulation of PKC genes and isozymes in cardiovascular tissues during early stages of experimental diabetes. Physiol Genomics 2003; 15: 139-146
• 17 Simonis G, Briem SK, Schoen SP. et al. Protein kinase C in the human heart: differential regulation of the isoforms in aortic stenosis or dilated cardiomyopathy. Mol Cell Biochem 2007; 305: 103-111
• 18 Bowling N, Walsh RA, Song G. et al. Increased protein kinase C activity and expression of Ca2+-sensitive isoforms in the failing human heart. Circulation 1999; 99: 384-391
• 19 Min W, Bin ZW, Quan ZB. et al. The signal transduction pathway of PKC/NF-kappa B/c-fos may be involved in the influence of high glucose on the cardiomyocytes of neonatal rats. Cardiovasc Diabetol 2009; 11: 8
• 20 Kim MH, Jung YS, Moon CH. et al. Isoform-specific induction of PKC-epsilon by high glucose protects heart-derived H9c2 cells against hypoxic injury. Biochem Biophys Res Commun 2003; 309: 1-6
• 21 Chintalgattu V, Katwa LC. Role of protein kinase C-δ in 26 angiotensin II induced cardiac fibrosis. Biochem Biophys Res Commun 2009; 386: 612-616
• 22 Teerlink JR, Cotter G, Davison BA. et al. RELAXin in Acute Heart Failure (RELAX-AHF) Investigators. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): A randomised, placebo-controlled trial. Lancet 2013; 381: 29-39
• 23 Olson ER, Shamhart PE, Naugle JE. et al. Angiotensin II-induced extracellular signal-regulated kinase 1/2 activation is mediated by protein kinase C and intracellular calcium in adult rat cardiac fibroblasts. Hypertension 2008; 51: 704-711
• 24 Geraldes P, King GL. Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res 2010; 106: 1319-1331
• 25 Kikuchi C, Kajikuri J, Hori E. et al. Aortic superoxide production at the early HG stage in a rat type 2 diabetes model and the effects of pravastatin. Biol Pharm Bull 2014; 37: 996-1002
• 26 Song P, Yang S, Xiao L. et al. PKCδ promotes high glucose induced renal tubular oxidative damage via regulating activation and translocation of p66Shc. Oxid Med Cell Longev 10: 1-11
• 27 Braun MU, Mochly-Rosen D. Opposing effects of δ- and ζ-protein kinase C isozymes on cardiac fibroblast proliferation: Use of isozyme-selective inhibitors. J Mol Cell Cardiol 2003; 35: 895-903
• 28 He Z, Way KJ, Arikawa E. et al. Differential regulation of angiotensin II-induced expression of connective tissue growth factor by protein kinase C isoforms in the myocardium. J Biol Chem 2005; 280: 15719-15726
• 29 Churchill EN, Mochly-Rosen D. The roles of PKCdelta and epsilon isoenzymes in the regulation of myocardial ischaemia/reperfusion injury. Biochem Soc Trans 2007; 35: 1040-1042
• 30 He Z, Way KJ, Arikawa E. et al. Differential regulation of angiotensin II-induced expression of connective tissue growth factor by protein kinase C isoforms in the myocardium. J Biol Chem 2005; 280: 15719-15726
• 31 Chen C, Du J, Feng W. et al. β-Adrenergic receptors stimulate interleukin-6 production through Epac-dependent activation of PKCδ/p38 MAPK signaling in neonatal mouse cardiac fibroblasts. Br J Pharmacol 2012; 166: 676-688